Promising Results In GSK Study Could Break Years Of TB Vaccine Deadlock
Executive Summary
GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.
You may also be interested in...
Big Pharma Advances Efforts In TB But Pricing Stays Key Concern
Price cuts, new treatments for TB and alliances to improve access to these medicines were among the key talking points at the recently concluded Union World Conference on Lung Health in India. TB survivors and activists were also vocal and pressed hard for their demands to be heard.
UN's TB Plan Emphasizes Drug Development Collaboration, Universal Access To Treatment
IFPMA attends UN General Assembly high-level meeting on tuberculosis, commits to partner on prevention, support systems, and research.
TB or not TB: Is Emergent‘s vaccine the solution?
MVA85A, the leading investigational vaccine against TB, has failed to replicate early promising efficacy seen in adults in a new Phase IIb study in infants published this week in The Lancet. But despite the disappointment, experts say this should not spell the end for the product, and the study should provide useful pointers for planning other trials and vaccination strategies.